文献速递胸部肿瘤

SELECT:厄洛替尼辅助治疗切除后表皮生长因子受体突变非小细胞肺癌的II期试验

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2018-11-16

这项开放标签II期试验纳入100例切除后IA-IIIA期EGFR突变非小细胞肺癌患者,在标准辅助化疗(联合或不联合放疗)后给予厄洛替尼150 mg/日共2年。2年无病生存率为88%,5年无病生存率56%,5年总生存率86%,复发40例中仅4例发生在厄洛替尼治疗期间。

要点

  • 切除后EGFR突变NSCLC患者接受2年辅助厄洛替尼,2年无病生存率达88%。
  • 40%患者需将厄洛替尼减量至100 mg/日,16%减至50 mg/日,69%完成既定2年疗程。
  • 复发者再活检仅1例检出T790M突变,65%复发患者再次使用厄洛替尼中位13个月。

核心结论

  • EGFR突变NSCLC患者接受辅助厄洛替尼相比历史基因型匹配对照,2年无病生存率改善。
  • 接受辅助厄洛替尼期间复发少见,复发后再次挑战厄洛替尼的患者获得持久获益。

研究设计与样本

  • 开放标签II期试验,计划入组100例,主要终点为2年无病生存率大于85%(历史数据为76%)。
  • 2008年1月至2012年5月在7个中心入组100例切除后IA-IIIA期(美国癌症联合委员会分期系统第7版)EGFR突变NSCLC患者。
  • 患者在标准辅助化疗联合或不联合放疗后接受厄洛替尼150 mg/日共2年。

主要发现

  • 分期分布:IA期13%、IB期32%、IIA期11%、IIB期16%、IIIA期28%。
  • 毒性为厄洛替尼典型毒性,无4级或5级不良事件;40%患者需减量至100 mg/日,16%减至50 mg/日,69%完成既定2年疗程。
  • 中位随访5.2年,2年无病生存率88%(I期96%、II期78%、III期91%);中位无病生存期和总生存期未达到。
  • 5年无病生存率56%(95%CI 45%至66%),5年总生存率86%(95%CI 77%至92%)。
  • 40例复发,其中仅4例发生在厄洛替尼治疗期间;停药后中位复发时间25个月;24例复发再活检者中仅1例检出T790M突变;26例(65%)复发患者再次使用厄洛替尼,中位13个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in advanced EGFR-mutant non-small-cell lung cancer (NSCLC), we tested adjuvant erlotinib in patients with EGFR-mutant early-stage NSCLC. MATERIALS AND METHODS: In this open-label phase II trial, patients with resected stage IA to IIIA (7th edition of the American Joint Committee on Cancer staging system) EGFR-mutant NSCLC were treated with erlotinib 150 mg per day for 2 years after standard adjuvant chemotherapy with or without radiotherapy. The study was designed for 100 patients and powered to demonstrate a primary end point of 2-year disease-free survival (DFS) greater than 85%, improving on historic data of 76%. RESULTS: Patients (N = 100) were enrolled at seven sites from January 2008 to May 2012; 13% had stage IA disease, 32% had stage IB disease, 11% had stage IIA disease, 16% had stage IIB disease, and 28% had stage IIIA disease. Toxicities were typical of erlotinib; there were no grade 4 or 5 adverse events. Forty percent of patients required erlotinib dose reduction to 100 mg per day and 16% to 50 mg per day. The intended 2-year course was achieved in 69% of patients. The median follow-up was 5.2 years, and 2-year DFS was 88% (96% stage I, 78% stage II, 91% stage III). Median DFS and overall survival have not been reached; 5-year DFS was 56% (95% CI, 45% to 66%), 5-year overall survival was 86% (95% CI, 77% to 92%). Disease recurred in 40 patients, with only four recurrences during erlotinib treatment. The median time to recurrence was 25 months after stopping erlotinib. Of patients with recurrence who underwent rebiopsy (n = 24; 60%), only one had T790M mutation detected. The majority of patients with recurrence were retreated with erlotinib (n = 26; 65%) for a median duration of 13 months. CONCLUSION: Patients with EGFR-mutant NSCLC treated with adjuvant erlotinib had an improved 2-year DFS compared with historic genotype-matched controls. Recurrences were rare for patients receiving adjuvant erlotinib, and patients rechallenged with erlotinib after recurrence experienced durable benefit.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pennell NA, Neal JW, Chaft JE, et al. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. J Clin Oncol. 2018. PMID: 30444685. doi:10.1200/JCO.18.00131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。